-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
DNA -X- _ O
vaccine -X- _ O
immunogenicity -X- _ O
has -X- _ O
been -X- _ O
limited -X- _ O
by -X- _ O
inefficient -X- _ O
delivery. -X- _ O
Needle-free -X- _ B-Intervention
delivery -X- _ I-Intervention
of -X- _ I-Intervention
DNA -X- _ I-Intervention
using -X- _ I-Intervention
a -X- _ I-Intervention
CO -X- _ I-Intervention
( -X- _ I-Intervention
2 -X- _ I-Intervention
) -X- _ I-Intervention
-powered -X- _ I-Intervention
Biojector® -X- _ I-Intervention
device -X- _ I-Intervention
was -X- _ O
compared -X- _ O
to -X- _ O
delivery -X- _ B-Comparison
by -X- _ I-Comparison
needle -X- _ I-Comparison
and -X- _ I-Comparison
syringe -X- _ I-Comparison
and -X- _ O
evaluated -X- _ O
for -X- _ O
safety -X- _ O
and -X- _ O
immunogenicity. -X- _ O
METHODS -X- _ O
: -X- _ O
Forty -X- _ O
adults -X- _ O
, -X- _ O
18–50 -X- _ O
years -X- _ O
, -X- _ O
were -X- _ O
randomly -X- _ O
assigned -X- _ O
to -X- _ O
intramuscular -X- _ B-Comparison
( -X- _ I-Comparison
IM -X- _ I-Comparison
) -X- _ I-Comparison
vaccinations -X- _ I-Comparison
with -X- _ I-Comparison
DNA -X- _ I-Comparison
vaccine -X- _ I-Comparison
, -X- _ O
VRC- -X- _ B-Intervention
HIVDNA016-00-VP -X- _ I-Intervention
, -X- _ I-Intervention
( -X- _ I-Intervention
weeks -X- _ I-Intervention
0 -X- _ I-Intervention
, -X- _ I-Intervention
4 -X- _ I-Intervention
, -X- _ I-Intervention
8 -X- _ I-Intervention
) -X- _ I-Intervention
by -X- _ I-Intervention
Biojector® -X- _ I-Intervention
2000TM -X- _ I-Intervention
or -X- _ O
needle -X- _ B-Comparison
and -X- _ I-Comparison
syringe -X- _ I-Comparison
( -X- _ I-Comparison
N -X- _ I-Comparison
/ -X- _ I-Comparison
S -X- _ I-Comparison
) -X- _ I-Comparison
and -X- _ I-Comparison
boosted -X- _ I-Comparison
IM -X- _ I-Comparison
at -X- _ I-Comparison
week -X- _ I-Comparison
24 -X- _ I-Comparison
with -X- _ I-Comparison
VRC-HIVADV014-00-VP -X- _ I-Comparison
( -X- _ I-Comparison
rAd5 -X- _ I-Comparison
) -X- _ I-Comparison
with -X- _ I-Comparison
N -X- _ I-Comparison
/ -X- _ I-Comparison
S -X- _ I-Comparison
at -X- _ I-Comparison
10 -X- _ I-Comparison
( -X- _ I-Comparison
10 -X- _ I-Comparison
) -X- _ I-Comparison
or -X- _ I-Comparison
10 -X- _ I-Comparison
( -X- _ I-Comparison
11 -X- _ I-Comparison
) -X- _ I-Comparison
particle -X- _ I-Comparison
units -X- _ I-Comparison
( -X- _ I-Comparison
PU -X- _ I-Comparison
) -X- _ I-Comparison
. -X- _ O
Equal -X- _ O
numbers -X- _ O
per -X- _ O
assigned -X- _ O
schedule -X- _ O
had -X- _ O
low -X- _ O
( -X- _ O
≤500 -X- _ O
) -X- _ O
or -X- _ O
high -X- _ O
( -X- _ O
> -X- _ O
500 -X- _ O
) -X- _ O
reciprocal -X- _ O
titers -X- _ O
of -X- _ O
preexisting -X- _ O
Ad5 -X- _ O
neutralizing -X- _ O
antibody. -X- _ O
RESULTS -X- _ O
: -X- _ O
120 -X- _ B-Outcome
DNA -X- _ I-Outcome
and -X- _ I-Outcome
39 -X- _ I-Outcome
rAd5 -X- _ I-Outcome
injections -X- _ I-Outcome
were -X- _ I-Outcome
given -X- _ I-Outcome
; -X- _ I-Outcome
36 -X- _ I-Outcome
subjects -X- _ I-Outcome
completed -X- _ I-Outcome
follow-up -X- _ I-Outcome
research -X- _ I-Outcome
sample -X- _ I-Outcome
collections. -X- _ I-Outcome
IFN-γ -X- _ I-Outcome
ELISpot -X- _ I-Outcome
response -X- _ I-Outcome
rates -X- _ I-Outcome
were -X- _ I-Outcome
17 -X- _ I-Outcome
/ -X- _ I-Outcome
19 -X- _ I-Outcome
( -X- _ I-Outcome
89 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
for -X- _ I-Outcome
Biojector® -X- _ I-Outcome
and -X- _ I-Outcome
13 -X- _ I-Outcome
/ -X- _ I-Outcome
17 -X- _ I-Outcome
( -X- _ I-Outcome
76 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
for -X- _ I-Outcome
N -X- _ I-Outcome
/ -X- _ I-Outcome
S -X- _ I-Outcome
delivery -X- _ I-Outcome
at -X- _ I-Outcome
Week -X- _ I-Outcome
28 -X- _ I-Outcome
( -X- _ I-Outcome
4 -X- _ I-Outcome
weeks -X- _ I-Outcome
post -X- _ I-Outcome
rAd5 -X- _ I-Outcome
boost -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
The -X- _ I-Outcome
magnitude -X- _ I-Outcome
of -X- _ I-Outcome
ELISpot -X- _ I-Outcome
response -X- _ I-Outcome
was -X- _ I-Outcome
about -X- _ I-Outcome
3-fold -X- _ I-Outcome
higher -X- _ I-Outcome
in -X- _ I-Outcome
Biojector® -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
N -X- _ I-Outcome
/ -X- _ I-Outcome
S -X- _ I-Outcome
groups. -X- _ I-Outcome
Similar -X- _ I-Outcome
effects -X- _ I-Outcome
on -X- _ I-Outcome
response -X- _ I-Outcome
rates -X- _ I-Outcome
and -X- _ I-Outcome
magnitude -X- _ I-Outcome
were -X- _ I-Outcome
observed -X- _ I-Outcome
for -X- _ I-Outcome
CD8+ -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
not -X- _ I-Outcome
CD4+ -X- _ I-Outcome
T-cell -X- _ I-Outcome
responses -X- _ I-Outcome
by -X- _ I-Outcome
ICS. -X- _ I-Outcome
Env-specific -X- _ I-Outcome
antibody -X- _ I-Outcome
responses -X- _ I-Outcome
were -X- _ I-Outcome
about -X- _ I-Outcome
10-fold -X- _ I-Outcome
higher -X- _ I-Outcome
in -X- _ I-Outcome
Biojector-primed -X- _ I-Outcome
subjects. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
DNA -X- _ B-Outcome
vaccination -X- _ I-Outcome
by -X- _ I-Outcome
Biojector® -X- _ I-Outcome
was -X- _ I-Outcome
well-tolerated -X- _ I-Outcome
and -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
needle -X- _ I-Outcome
injection -X- _ I-Outcome
, -X- _ I-Outcome
primed -X- _ I-Outcome
for -X- _ I-Outcome
greater -X- _ I-Outcome
IFN-γ -X- _ I-Outcome
ELISpot -X- _ I-Outcome
, -X- _ I-Outcome
CD8+ -X- _ I-Outcome
T-cell -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
antibody -X- _ I-Outcome
responses -X- _ I-Outcome
after -X- _ I-Outcome
rAd5 -X- _ I-Outcome
boosting. -X- _ I-Outcome
TRIAL -X- _ O
REGISTRATION -X- _ O
: -X- _ O
ClinicalTrials.gov -X- _ O
NCT00109629 -X- _ O

